Effectiveness and safety in Crohn's disease patients who were treated with CT-P13

被引：0
|
作者：
Choe, Y. H. [1 ]
Lee, S. -H. [2 ]
Park, D. I. [3 ]
Lee, J. H. [4 ]
Kim, H. J. [5 ]
Kim, Y. -H. [6 ]
Choi, C. H. [7 ]
Eun, C. S. [8 ]
Lee, S. J. [9 ]
Lee, S. [9 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Dept Pediat, Samsung Med Ctr, Seoul, South Korea
[2] Esoo Hosp, Digest Endoscop Ctr, Cheonan Si, South Korea
[3] Kangbuk Samsung Hosp, Dept Internal Med, Seoul, South Korea
[4] Seoul Song Do Colorectal Hosp, Dept Internal Med, Seoul, South Korea
[5] Kyung Hee Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[6] Sungkyunkwan Univ, Sch Med, Dept Internal Med, Samsung Med Ctr, Seoul, South Korea
[7] Chung Ang Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[8] Hanyang Univ, Coll Med, Dept Internal Med, Guri Hosp, Guri, South Korea
[9] CELLTRION Inc, Incheon, South Korea
来源：
JOURNAL OF CROHNS & COLITIS | 2017年 / 11卷
关键词：
INFLIXIMAB;
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P500
引用
收藏
页码：S333 / S333
页数：1
相关论文
共 50 条
  • [41] Effectiveness and safety of ustekinumab in elderly Crohn's Disease patients
    Nunez, I. Ruiz
    Sauca, L. Morera
    Dominguez, R. E. Madrigal
    Andres, J. Barrio
    Santos, A. De Prado
    Roman, L. Mata
    Munoz, M. A. Marinero
    Alonso, J. Garcia
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1436 - i1436
  • [42] UNCHANGED INFLIXIMAB SERUM CONCENTRATIONS AFTER SWITCHING FROM THE ORIGINATOR INFLIXIMAB TO THE BIOSIMILAR CT-P13 IN PATIENTS WITH QUIESCENT CROHN'S DISEASE: A PROSPECTIVE STUDY
    Strik, Anne S.
    van de Vrie, W.
    Megen, Yvonne
    Minekus, Joanne
    Rispens, Theo
    D'Haens, Geert R.
    GASTROENTEROLOGY, 2017, 152 (05) : S66 - S66
  • [43] Safety and effectiveness of intravenous CT-P13 in inflammatory arthritis: post-marketing surveillance study in Thailand
    Mahakkanukrauh, Ajanee
    Chaiamnuay, Sumapa
    Koolvisoot, Ajchara
    Kitamnuayphong, Tassanee
    Manavathongchai, Siriporn
    Osiri, Manathip
    Louthrenoo, Worawit
    Uea-Areewongsa, Parichat
    Ahn, Keumyoung
    Jung, Nahyun
    Kim, Minkyung
    Lee, Seulgi
    Kim, Hanna
    Kim, Sunghyun
    IMMUNOTHERAPY, 2023, 15 (14) : 1143 - 1155
  • [44] Unchanged infliximab serum concentrations after switching from the reference infliximab to the biosimilar CT-P13 in patients with quiescent Crohn's disease: a prospective study
    Strik, A.
    van de Vrie, W.
    van Megen, Y.
    Bloemsaat-Minekus, J.
    Rispens, T.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S420 - S420
  • [45] Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients
    Pugliese, Daniela
    Guidi, Luisa
    Privitera, Giuseppe
    Bertani, Lorenzo
    Tolusso, Barbara
    Papparella, Luigi Giovanni
    Maltinti, Simona
    Di Mario, Clara
    Onali, Sara
    Ceccarelli, Linda
    Rapaccini, Gian Lodovico
    Scaldaferri, Franco
    Gremese, Elisa
    Gasbarrini, Antonio
    Costa, Francesco
    Armuzzi, Alessandro
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (01) : 97 - 104
  • [46] Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar(CT-P13) in patients with inflammatory bowel disease
    María Fernanda Guerra Veloz
    Federico Argüelles-Arias
    Luisa Castro Laria
    Belén Maldonado Pérez
    Antonio Benítez Roldan
    Raúl Perea Amarillo
    Vicente Merino Bohórquez
    Miguel Angel Calleja
    ángel Caunedo álvarez
    ángel Vilches Arenas
    World Journal of Gastroenterology, 2018, (46) : 5288 - 5296
  • [47] Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
    Guerra Veloz, Maria Fernanda
    Arguelles-Arias, Federico
    Castro Laria, Luisa
    Maldonado Perez, Belen
    Benitez Roldan, Antonio
    Perea Amarillo, Raul
    Merino Bohorquez, Vicente
    Angel Calleja, Miguel
    Caunedo Alvarez, Angel
    Vilches Arenas, Angel
    WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (46) : 5288 - 5296
  • [48] Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study
    Ye, Byong Duk
    Pesegova, Marina
    Alexeeva, Olga
    Osipenko, Marina
    Lahat, Adi
    Dorofeyev, Andriy
    Fishman, Sigal
    Levchenko, Olena
    Cheon, Jae Hee
    Scribano, Maria Lia
    Mateescu, Radu-Bogdan
    Lee, Kang-Moon
    Eun, Chang Soo
    Lee, SangJoon
    Lee, Sung Young
    Kim, HoUng
    Schreiber, Stefan
    Fowler, Heather
    Cheung, Raymond
    Kim, Young-Ho
    LANCET, 2019, 393 (10182): : 1699 - 1707
  • [49] Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results
    Kim, Y. H.
    Ye, B. D.
    Pesegova, M.
    Alexeeva, O.
    Osipenko, M.
    Lahat, A.
    Dorofeyev, A.
    Salamon, A.
    Fishman, S.
    Levchenko, O.
    Cheon, J. H.
    Scribano, M. L.
    Mateescu, R. -B.
    Lee, K. M.
    Eun, C. S.
    Lee, S. J.
    Lee, S. Y.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S62 - S62
  • [50] Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World Outcomes
    Plevris, Nikolas
    Jones, Gareth R.
    Jenkinson, Philip W.
    Lyons, Mathew
    Chuah, Cher S.
    Merchant, Lynne M.
    Pattenden, Rebecca J.
    Watson, Eleanor F.
    Ho, Gwo-Tzer
    Noble, Colin L.
    Din, Shahida
    Shand, Alan G.
    Arnott, Ian D.
    Lees, Charlie W.
    DIGESTIVE DISEASES AND SCIENCES, 2019, 64 (06) : 1660 - 1667
12345